CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral...

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory...

Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy...

Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA®) significantly...

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition represent a...

Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART) therapy CTL019 in certain types of relapsed or refractory...

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced results from a new analysis of the pivotal Phase 3 trial, PERSIST-1,...

Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in...

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health...

WHO: Andre Goy, M.D., M.S., Chairman, John Theurer Cancer Center and Chief, Division of Lymphoma, Hackensack University Medical Center; Andrew L. Pecora, MD, FACP, CPE, Vice President of Cancer...